Visar resultat för..."Derivatives Vision"

The over-the-counter (OTC) derivatives market has captured the attention of regulators after the Global Financial Crisis due to the risk it poses to financial stability. Under the post-crisis regulatory reform the concentration of business, and risks, among a few major players is changed by the concentration of a large portion of transactions in the new market infrastructures, the Central Counterparties (CCPs).This book, for the first time, analyses the regulatory response of the United Kingdom and the United States, the two largest centres of OTC derivatives transactions, and highlights their shortcomings. The book uses a normative risk-based approach to regulation as a methodological lens to analyse the UK regime of CCPs in the OTC derivatives market. It specifically focuses on prudential supervision and conduct of business rules governing OTC derivatives transactions and the move towards enhancing the use of central clearing. The resulting analysis, from a normative risk based approach, suggests that the UK regime for CCPs does not fulfil what would be expected if a coherent risk based approach was taken.Our comments on the Dodd-Frank Act highlight that the incoherent adoption of risk-based approach to regulation affects the effectiveness of the US regime for CCPs. Such a regime does not follow the pace of events of ‘innovation risk’; in particular, the foreseeable changes FinTech will bring to the OTCDM and central clearing services. The second inadequacy of the US regime concerns the dual regulatory structure of the CFTC and the SEC, and the inadequate adoption of different and not well-coordinated regulatory strategies. We also analyse the cross-border implications of the US regime for non-US CCPs that provide clearing services to US market participants. Finally, we study the negative effects of the absence of a clearly defined resolution regime for CCPs.

The over-the-counter (OTC) derivatives market has captured the attention of regulators after the Global Financial Crisis due to the risk it poses to financial stability. Under the post-crisis regulatory reform the concentration of business, and risks, among a few major players is changed by the concentration of a large portion of transactions in the new market infrastructures, the Central Counterparties (CCPs).This book, for the first time, analyses the regulatory response of the United Kingdom and the United States, the two largest centres of OTC derivatives transactions, and highlights their shortcomings. The book uses a normative risk-based approach to regulation as a methodological lens to analyse the UK regime of CCPs in the OTC derivatives market. It specifically focuses on prudential supervision and conduct of business rules governing OTC derivatives transactions and the move towards enhancing the use of central clearing. The resulting analysis, from a normative risk based approach, suggests that the UK regime for CCPs does not fulfil what would be expected if a coherent risk based approach was taken.Our comments on the Dodd-Frank Act highlight that the incoherent adoption of risk-based approach to regulation affects the effectiveness of the US regime for CCPs. Such a regime does not follow the pace of events of ‘innovation risk’; in particular, the foreseeable changes FinTech will bring to the OTCDM and central clearing services. The second inadequacy of the US regime concerns the dual regulatory structure of the CFTC and the SEC, and the inadequate adoption of different and not well-coordinated regulatory strategies. We also analyse the cross-border implications of the US regime for non-US CCPs that provide clearing services to US market participants. Finally, we study the negative effects of the absence of a clearly defined resolution regime for CCPs.

This Expert Guide gives you the knowledge, methods and techniques to develop and manage embedded systems successfully. It shows that teamwork, development procedures, and program management require unique and wide ranging skills to develop a system, skills that most people can attain with persistence and effort.

With this book you will:

Understand the various business aspects of a project from budgets and schedules through contracts and market studies Understand the place and timing for simulations, bench tests, and prototypes, and understand the differences between various formal methods such as FMECA, FTA, ETA, reliability, hazard analysis, and risk analysis Learn general design concerns such as the user interface, interfaces and partitioning, DFM, DFA, DFT, tradeoffs such as hardware versus software, buy versus build, processor choices, and algorithm choices, acquisition concerns, and interactions and comparisons between electronics, functions, software, mechanics, materials, security, maintenance, and support Covers the life cycle for developing an embedded system: program management, procedures for design and development, manufacturing, maintenance, logistics, and legal issues Includes proven and practical techniques and advice on tackling critical issues reflecting the authors' expertise developed from years of experience

Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 44, first published in 1977, presents clinicians and medical investigators with a critical survey of new data and trends in adverse drug reactions and interactions. Topics covered in this new release include Thyroid hormones, Iodine and Iodides, and Antithyroid Drugs, Side Effects of Antidepressant Medications, Side Effects of Lithium, Side Effects of Opioid Analgesics and Narcotic Antagonists, Side Effects of Beta-lactams and Tetracyclines, Side effects of Anti-diabetic Drugs, Vaccines, Side Effects of Neuromuscular Blockings Agents and Skeletal Muscle Relaxants, and much more.

Other chapters cover General Anesthetics and Therapeutic Gases, Drugs that Act on the Respiratory Tract, Positive Inotropic Drugs and Drugs Used in Dysrhythmias, Metals and Metal Antagonists, Antiseptic Drugs and Disinfectants with special scrutiny of COVID-19 pandemic related side effects, Drugs in tuberculosis and leprosy, Anthelminthic drugs, Blood and blood treatments, and a variety of other topics.

Provides a critical yearly survey of the new data and trends regarding the side effects of drugs Authored and reviewed by worldwide pioneers in the clinical and practice sciences Presents an essential clinical guide on the side effects of drugs for practitioners and healthcare professionals alike